1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry

M Falk,M Tiemann,J Roeper,A Stenzinger,M Thomas,F Griesinger,L Heukamp,P Christopoulos

doi:10.1016/j.annonc.2020.08.1658

1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry

M Falk, M Tiemann + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1658

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
License type: elsevier-specific: oa user license

Affiliation: Pathologie Hamburg-West, Pius Hospital Oldenburg, Carl von Ossietzky University of Oldenburg, University Hospital Heidelberg, Heidelberg University

#3rd Generation TKI #Real World Data + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry

Full Text